Apellis Pharmaceuticals, Inc. (APLS) Stock
Apellis Pharmaceuticals, Inc.
Company profile
Apellis Pharmaceuticals reported revenue of $1.00 billion for fiscal year 2025. Our analysis of its filings shows revenue growing from $396.59 million in fiscal year 2023 to $1.00 billion in fiscal year 2025, 59.1% a year on average.
What stands out
- Revenue rose 28.5% in fiscal year 2025, from $781.37 million in fiscal year 2024, after a rise of 97.0% the year before.
- It returned to a profit in fiscal year 2025, $22.39 million, after 4 years of net losses ($197.88 million in fiscal year 2024).
- It spent $295.85 million on research and development in fiscal year 2025, 29.5% of its revenue.
Figures from company filings; latest fiscal year ended December 31, 2025.
Largest shareholders
- Wellington Management Co. LLP10.89%
- Morningside Group Ltd.10.14%
- Avoro Capital Advisor LLC9.68%
- EcoR1 Capital, LLC9.42%
- Morgan Stanley Investment Management, Inc.7.72%
Share of the company, as of November 8, 2025
In the news
- Biogen scales back Apellis programs, trims research roles after $5.6 billion buyoutReuters ·
- Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
- Sobi Receives Positive CHMP Opinion for Aspaveli® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN
- Apellis Pharmaceuticals (APLS): Valuation Check After Positive EMPAVELI Kidney Data and New FDA Approval
How much revenue does Apellis Pharmaceuticals make?
Apellis Pharmaceuticals reported $1.00 billion in revenue for fiscal year 2025, up 28.5% from $781.37 million in fiscal year 2024.
What companies are similar to Apellis Pharmaceuticals?
Listed companies of a similar size in the same industry (eye treatment pharmaceuticals) include Regeneron Pharmaceuticals, Inc. (REGN), Bausch + Lomb Corporation (BLCO), Kodiak Sciences Inc. (KOD), Belite Bio, Inc (BLTE).
How has Apellis Pharmaceuticals' revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2021, $66.56 million; FY2022, $75.42 million; FY2023, $396.59 million; FY2024, $781.37 million; FY2025, $1.00 billion.
Has Apellis Pharmaceuticals made a profit in recent years?
Net income by fiscal year: FY2021, a loss of $746.35 million; FY2022, a loss of $652.17 million; FY2023, a loss of $528.63 million; FY2024, a loss of $197.88 million; FY2025, $22.39 million. It reported a net loss in 4 of these 5 years.
Data as of .
How to cite: DataPorium, “Apellis Pharmaceuticals, Inc. (APLS)”, data as of Dec 31, 2025, https://dataporium.tech/stocks/APLS